Aptevo Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z
Aptevo Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for The Molecule in developing novel bispecific and trispecific immunotherapies for the treatment of cancer (Preclinical) using Bispecific.
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| Differentiated by Design | developing novel bispecific and trispecific immunotherapies for the treatment of cancer | Bispecific | n/a | Public pipeline row |
| The ADAPTIR Difference | n/a | Bispecific | n/a | Public pipeline row |
| APVO603 | n/a | Bispecific | n/a | Public pipeline row |
| OX40 | n/a | n/a | n/a | Public pipeline row |
| APVO442 | n/a | n/a | n/a | Public pipeline row |
| Highlights | n/a | n/a | n/a | Public pipeline row |
| The Molecule | n/a | n/a | Preclinical | Public pipeline row |
| APVO711 | broad potential therapeutic use for a number of different types of solid tumors | n/a | n/a | Public pipeline row |
No public catalyst rows matched this view yet.
Estimated cash runway: Runway 6-12 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT05934539 | Phase 1 | Phase 2 | UNKNOWN | 56 | 2024-01-01 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.